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SYNOPSIS





"STUDIES ON SOME COMPOUNDS OF MEDICINAL INTEREST"
A comprehensive summary of the work to be incorporated in the thesis
entitled "STUDIES ON SOME COMPOUNDS OF MEDICINAL
INTEREST" included substituted aminoindan and dibenzo thiazepine deriva-
tives.
The aim of research is to be develop new bioactive entitles, especially with
antimicrobial activities. Numerous compounds like sulphonamides, aryl amide,
imidazolines, ihalcones, iyrazolines, pyrimidines have been prepared using
substituted aminoindan and dibenzo thiazepine. Above compounds
possess wide antiinflammatory, antimicrobial, antimalarial, anticonvalsant.
antipyretic, antitumor, anticancer, antidepresant activity.
Some new synthesised compounds, which have been described as under.
PART - I : STUDIES ON ARYLAMIDE
Arylamide derivatives represents one of the modest classes of
compounds possessing wide range of therapeutic activities such as antihista-
mine, antiinflammatory, anticonvalsent, antimicrobial, antituberculer etc. With a
view of getting better therapeutic agents and to evaluate its pharmacological
profile different type of arylamide have been prepared, which have been
described as under.
SECTION - I : Synthesis and biological screening of 1-N-aroyl
aminoindan.
1
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Arylamide of Type (I) have been synthesised by the condensation
of 1- aminoindan with aroyl chloride.
PART - II : STUDIES ON SULPHONAMIDES
Sulphonamide derivatives have been found to be associated with
various pharmacological activity such as antibacterial, antimalarial, antiviral,
anticonvulsant etc. These finding encouraged us to synthesised some new
sulphonamide derivatives as under.
SECTION - I : Synthesis and biological screening of 1-N-aryl
sulphonamido indan.
Sulphonamides of Type - (II) have been synthesised by the
condensation of 1- aminoindan with arylsulphonyl chloride.
PART - III : STUDIES ON 5 - OXO - IMIDAZOLINES
5-Oxo-imidazoline derivatives have been reported to be active as
anticonvulsant, potent CNS depressant, antiinflammatory, anticancer,  hypnotics
etc. In view of the above finding some new 5-oxo-imidazoline derivatives have
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SECTION -I : Synthesis and biological screening of 4-arylidene-1-
(indan-1'-yl)-2-phenyl-5-oxo imidazolines.
5-Oxo imidazolines of Type-(III) have been synthesised by the
condensation of 1- aminoindan with different oxazolone.
PART - IV : STUDIES ON 4 - THIAZOLIDINONES
4-Thiazolidinones derivatives are associated with various biological
activities such as antitubercular, anticonvulsent, antifungal, antibacterial,
antidiabetic etc. In view of getting to synthesis new 4-thiazolidinones
derivatives have been described are as under.
SECTION - I : Synthsis and biological screening of 1-substituted
benzylidene aminoindan
Schiff's bases of Type - (IV) have been synthesised by the condensation
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SECTION - II : Synthesis and biological screening of 2-Aryl - 3
indanyl-5-H-4- thiazolidinones
4-Thiazolidinones of Type-(V) have been synthesized by the condensation
of schiff's bases of Type-(IV) with thioglycolic acid.
SECTION - III : Sythesis and biological screening of 2-aryl-3-indanyl-
5- carboxymethyl-4-thiazolidinones
4-Thiazolidinone derivatives of Type - (VI) have been synthesized
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SECTION - IV  : Synthesis and biological screening of
1-Substituted benzyl aminoindan.
The compounds of Type (VII) have been synthesised by the
reduction of Schiff's bases of Type - (IV) with anhydrous NaBH4.
PART - V : STUDIES ON  2 - AZETIDINONES.
Azetidinone derivatives represent one of the most active classes of
compounds possessing a wide spectrum of biological activities such as
antibiotic, antidepressant, sedative, hypnotic, anticonvulsant, herbicidal etc.
With a view to getting better therapeutic agents, we have synthesized
different type of 2- azetidinone derivatives which have been described as
under.
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The compounds of Type - (VIII) have been synthesized by the
reaction of Schiff's bases of Type-(IV) with chloroacetylchloride in
presence of triethyl amine as a catalyst.
PART - VI : STUDIES ON CHALCONES
Chalcones are phenyl styrylketones containing reactive
keto-ethylenic group (-C-CH=CH-). Literature survey reveals that chalcone
derivatives possess antibacterial, antiviral, antispasmodic etc. activities. In
view of getting to synthesis chalcone derivatives, which have been
described as under.
SECTION - I : Synthesis and biological screening of 11-{4'-[(3"-
   aryl)-2"propen-1"-one]- phenoxy} dibenzo [b,f]
   thiazepines.
The chalcone derivatives of Type (IX) have been synthesised by the
condensation of 11-(4'-acetylphenoxy) dibenzo [b,f] thiazepine with
aromatic aldehydes in presence of aq. NaOH.
PART - VII : STUDIES ON PYRAZOLINE
Pyrazoline derivatives possess broad spectrum of pharma-
cological activities, such as analgesic, antiinflammatory, anticonvulsant,
insecticidal, herbicidal, antimicrobial, antipyretic etc. Prompted by above
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SECTION - I : Synthesis and biological screening of 11-{4'-[(5"-
   aryl)-4"-5" dihydro-1"-(H)-pyrazol-3"-yl] phenoxy}-
  dibenz [b,f] thiazepines
Pyrazoline derivatives of Type-(X) have been synthesised by the
condensation of compounds of Type-(IX) with hydrazine hydrate.
PART - VIII : STUDIES ON PYRIMIDINES
Pyrimidine derivatives are associated with various biological
activities, such as  antifungal, antitubercular, antibacterial, herbicidal etc.
This valid observation led us to synthesis some new pyrimidine deriva-
tives, which have been described as under.
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Pyrimidine derivatives of Type-(XI) have been synthesised by
the reaction of the chalcones of Type - (IX) with thiourea in presence of
alcoholic potassium hydroxide.
The structures elucidation of the synthesized compounds have
been done on the basis of elemental analysis, IR, 1H NMR and mass
spectroscopy. The purity of the synthesised compunds checked by TLC.
All the compounds have been also evaluated for their antimicro-
bial activity towards Gram +ve and Gram-ve bacteria and also evaluated
antifungal activity. The antimicrobial activity of the synthesised compounds
have been  compared with known standard drugs.
8
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STUDIES ON SOME COMPOUNDS OF MEDICINAL INTEREST
INTRODUCTION
Medicinal chemistry is a science whose roots lie in all branches of
chemistry and biology. On this basis it attempts to establish relationships
between chemical structure and biological activity and to link biodynamic
behaviour to the chemical reactivity and physical properties of therapeutic
agents. Medicinal chemistry also involves the isolation, characterization and
synthesis of compounds that can be used in medicine for the prevention,
treatment and cure of disease.
The word "drug" is derived from the french word "drogue" which means
a dry herb. According to "WHO", a drug may be defined as "Any substance
or product which is used or intended to be used for modifying or exploring
physiological system or pathological status for the benefit of the recipient".
Pure organic compounds, natural or synthetic, together with the
so-called organometallics are the chief source of agents for the cure, the
mitigation or the prevention of disease today. These remedial agents have their
origin in a number of ways, (1) from naturally occuring materials of both plant
and animal origin and (2) from the synthesis of organic compounds whose
structures are closely related to those of naturally occuring compounds (e.g.
morphine, atropine, steroids and cocaine) that have been shown to possess
useful medicinal properties.
The rise of synthetic organic chemistry in the second half of the
nineteenth century led to an examination of the physiological properties of a
large number of substance having no counterpart in nature. One important
period of development in this subject was the two decades 1880-1900 which
showed the introduction of Knorr's antipyrine (1883) and Dreser's aspirin (1899),
10
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together with the accidental discovery in 1888 of the earliest synthetic hypnotic
sulphonal, although it was not until 1904 that V. Mering and Fischer
discovered diethyl barbituric acid (called veronal). Since then tens of thousand
of synthetic chemicals have been examined for their physiological activity and
of these, thousands have been introduced into practice as drugs.
A drug is a substance with an abnormal effect on certain body functions
e.g. strychnine stimulates the action of heart and aspirin still its action. Since
both of them effects abnormally, the two compounds are known as drugs.
Chemical sciences contributed extensively new discoveries leading to useful
drugs since after 1930. The modern concept of drug discovery started in 1933
by Gerhand Domagk with his finding of 'Prontosil Red' a compound responsi-
ble for the antibacterial activity. The advent of sulfonamides drew attention to
the differential activity of various chemicals towards bacterial and human cells
Some heterocyclic compounds must ideally have a broad spectrum of
activity with a rapid bactericidal action. We must always continue to search
new heterocyclic molecules and identify its respective drugs activity. To take
the care for synthesis new heterocyclic molecules a lower toxicity, a partial or
total absence of undesirable side effects, more neutritive value, improved
stability, a decrease in production cost and chek the qualitative or quantitative
improvement in activity with standard drugs.
1-aminoindan derivatives have been proposed to have some activity in
the central nervous system (CNS). Some derivatives show antiallergic,
antispasmodic, local anesthetic, antiinflammatory and vasodilatory activity.
Dibenzo [b,f] thiazepine derivatives  have been reported as a valuable
medicines e.g. quetiapine and tianeptine in the treatment of depression and
schizophrenia (antipsychotic) respectively.
11
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AIMS AND OBJECTIVES :
In the pharmaceutical field, there is a need for new and novel chemical
inhibitors of biological functions. Our efforts are focused on the introduction
of chemical diversity in the molecular frame work in order to synthesising
pharmacologically interesting compounds of widely different composition.
During the course of research work looking to the applications of the
compounds, several entities, have been designed, generated and characterised
using spectral studies. The aims and objectives of the work carried out are as
under.
(1) To synthesise pharmacologically active entities like arylamide,
sulphonamides, imidazolines, thiazolidinones, azetidinones, chalcones,
pazolines, pyrimidines bearing 1-aminoindan and dibenzo [b,f] thiazepine
moiety.
(2) To characterise these compounds for structural elucidation using
spectroscopic technique like IR, 1H NMR and Mass spectral studies.
(3) To check the purity of all compounds using thin layer chromatography.
(4) To evaluate antibacterial and antifungal activity of new synthesied
compounds with MIC.
The research work is presented as studies on 1-aminoindan and dibenzo
[b,f]  thiazepine derivatives.
PART - I : STUDIES ON ARYLAMIDE
PART - II : STUDIES ON SULPHONAMIDES
PART -III : STUDIES ON 5-OXO-IMIDAZOLINES
PART- IV : STUDIES ON 4-THIAZOLIDINONES
PART-V : STUDIES ON 2-AZETIDINONES
PART-VI : STUDIES ON CHALCONES
PART-VII : STUDIES ON PYRAZOLINES
PART - VIII : STUDIES ON PYRIMIDINES
12
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STUDIES ON ARYLAMIDE
INTRODUCTION
The aryl substitution products of ammonia are arylamide (R-CONH-)
derivatives, amides (-CO-NH-) derivatives, urea (-NH-CO-NH-)derivatives,
diamides (-CO-NH-CO-NH-) derivatives of carbonic acid are several naturally
occurring products. The proteins and peptides are linear structure of cyclic
polyamides. The alkaloids of piperine and chavicine are N-substituted amide
of unsaturated acids. Amides derived from polyacetylenic acids have been
isolated from certain fungi1. N-Isobutyl amide of certain highly unsaturated
aliphatic acid shows insecticidal activity2 and occur in plants.
SYNTHETIC ASPECT :
Several methods are reported in literature3,4 for the preparation of aryl
acetamides.
THERAPEUTIC IMPORTANCE :
Amides, aryl amide, heterocyclic aryl amide  derivatives showed
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Bartuleweiz et al15 have assessed arylamide as potential antitumor and
antibiotics. Dekeysefi et al16 have prepared novel arylamide derivatives (A)
and studied their immunomodulator activity.
Sanderson Philip E. J. and Co-workers17 have synthesised arylamide
and  studied their biological activity. Moloney Brian Anthony et al18 have
synthesised & studied their pharmacological activity, which have been found
as an antiulceragent. Foster James and Co-workers19 have synthesised some
new arylamide and reported as anticonvulsant. A. R. Mulik and co-workers20
have studied some arylamides showing antibiotic activity. Bridge Gory et al21
have prepared some arylamide and reported their anti-HIV activity. Laura and
co-workers22 have synthesised arylamide derivatives and evaluated its
antibacterial activities. M. Fanrong et al23 have synthesised arylamide
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Cudahy et al24 have synthesised arylamide and evaluated its antiviral
activity. Lau Jespers et al25 have reported arylamide as glucokinase (GK)
activators. A. Flohr et al.26 have synthesised arylamide as human adenosine
receptor.
A. R. Parikh et al27-31 have synthesised various arylamide derivatives  and
reported as antimicrobial agents.
Q. Liyuan et al32 have been synthesisd 1,4-bis (p-aminobenzoyl)-piperazine.
Y. Takashi et al33 have been reported arylamide derivatives gave receptor
antagonistic activity.
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A.J. Baxi et al35 have been synthesised various arylamide derivatives
and reported their antimicrobial activity.
17
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N AROYL
AMINOINDAN.
Aryl amide represent one of the important classes of compounds having a
broad spectrum of biological activities. In view of getting better therapeutic
agents, the synthesis of 1-N-aroyl aminoindan of Type-(I) have been
synthesised by the condensation of 1-aminoindan with aroyl chloride.
The constitution of the products were supported by the elemental analysis,
IR, 1H NMR and Mass spectral studies. The products were tested for their
antimicrobial activity with  MIC.
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NMR SPECTRAL STUDY OF 1-N-(4'-METHOXY BENZOYL)
AMINOINDAN
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EXPERIMENTAL
SYNTHESIS OF 1-N-AROYAL AMINOINDAN
(A) Synthesis of 1-N-4'-Methoxy benzoyl aminoindan.
A mixture of 1-aminoindan (1.33 gm, 0.01M) and 4-methoxy bezoyl
chloride (1.70 gm, 0.01 M) in dry pyridine (20 ml) was refluxed for 2 hrs. The
resulting mixture was poured into crushed ice and neutralised with HCl. The
product was filtered, washed with cold water and crystalised from methanol
Yield : 61.24 %, M.P. : 147oC (Found : C:76.36, H: 6.30, N: 5.19 % ;
C17 H17O2N calcd. C: 76.40, H : 6.36; N : 5.24 %)
Similarly other arylamide have been synthesised. The physical constants
are recorded in Table No. 1.
(B) Biological Screening of 1-N-aroyl aminoindan
The antimicrobial testing was  carried out as describe in Part-I,
Section-I, Page : No. 26-29.
The minimum inhibition concentration is recorded in Table No. 2.
25
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ANTIMICROBIAL ACTIVITY
Products : 1-N- aroyl aminoindan
Method : Broth dilution method36,37
Gram Positive Bacteria : Staphylococcus aureus and
Streptococcus pyogenes
Gram Negative Bacteria : Escherichia coli and
Pseudomonas aeruginosa
Fungi : Candida albicans
Solvent : DMSO
Standard Drugs : Ampicillin, Chloramphenicol, ciprofloxacin,
Griseofulvin
The antibacterial activity was compared with standard drugs viz.
Ampicillin, Chloramphenicol, Ciprofloxacin and antifungal activity was
compared with standard drug viz. Griseofulvin. The minimum inhibition
concentration was measured in g/ml. The MIC of standard drugs are
recorded in Part - I, Section - I, Page No. 29, Table No. A.
26
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(C) Antimicrobial activity of 1-N-aroyal aminoindan
Method : Broth dilution method
Materials and method :
1. All the synthesised compounds were used for antibacterial test proce
dures.





- Known antibacterial drugs control
- All MTCC cultures were tested against above mentioned known
drugs and new synthesized compounds.
- Mueller Hinton Broth was used as nutrient medium to grow and
dilute. The drug suspension for the test bacteria and sabaouraus
dextrose broth used for fungal nutrition.
- Inoculum size for test strain was adjust to 108 cfu [Colony Forming
Unit] per milli liter by comparing the turbidity.
- Following common standard strains were used for screening of
antibacterial and antifungal activities :
The strains were procured from Institute of  Microbial Technology.
Chandigarh.
Staphylococcus Aureus Gram + ve MTCC96
Streptococcus Pyogenes Gram + ve MTCC442
Escherichia Coli Gram - Ve MTCC 443
Pseudomonas Aeruginosa Gram - Ve MTCC 1688
Candida Albicans Fungus MTCC 227
D M SO  w as used as di luents / V ehicle to get desi red concentration of
drugs to test upon Standard bacterial  strains.
27
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Minimum Inhibition Concentration (MIC) :
The main advantage of the 'Broth Dilution Method for MIC
determination lies in the fact that it can readily be converted to determine the
MIC as well
(1) Serial dilutions were prepared in primary and secondary screening.
(2) The control tube containing no antibiotics is immediately sub cultured
[before inoculation] by spreading a loopful evenly over a quarter of plate
of  medium suitable for the growth of the test organism and put for
incubation at 37oC overnight. The tubes are then incubated overnight.
(3) The MIC of the control organism is read to check the accuracy of the
drug concentrations.
(4) The lowest concentration inhibiting growth of the organism is recorded
as the MIC.
(5) The amount of growth from the control tube before incubation [which
represents the original inoculum] is compared.
Methods used for primary and secondary screening :
Each synthesized compounds were diluted obtaining 2000 microgram /
ml concentration as a stock solution.
Primary screen :
In primary screening 1000 g/ml, 500  g/ml and 250 g/ml
concentration of the synthesized compounds were taken. The active
synthesized compounds found in this primary screening were further tested in
a second set of  dilution against all microorganisms.
Secondary screen :
The drugs found active in primary screening were similarly diluted to
obtain 200 g/ml, 100 g/ml, 50 g/ml, 12.5 g/ml, 6.250 g/ml and other
concentrations.
Reading Result :
The highest dilution showing at least 99% inhibition, zone is taken as
MIC. The result of  this is much affected by the size of the inoculum. The test
mixture should contain 108 organism/ml. The minimum inhibition
concentration (MIC) that displayed by standard drugs is recorded in
Table No. A.
28
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STUDIES ON SULPHONAMIDES
INTRODUCTION
The discovery of sulphonamides marked the begining of chemotherapeutic
era by making posible a direct attack on microbial infection.38 Sulphonamide
antibacterials continue to be used because they are effective, inexpensive and
free of super infection problems of the broad spectrum antibiotics.39
Sulphonamide have the general formula of R-SO2-           where R=organic
radical, R' and R" = Hydrogen or organic radical, depending upon the nature of
R.The sulphonamides are classified as aliphatic, aromatic and heterocyclic. The
aliphatic sulphonamides have not yet become important. Aromatic and
heterocyclic sulphonamides have achieved great commercial significance. Their
application in bacterial chemotherapy is well known. Considerable interest has
been shown in the chemistry of sulphonamides due to their as antibacterial,
anticancer, antimalarial, antifungal, antispasmodic, anticonvulsant, herbicidal,
antiinflammatory and analytical prepartion.
SYNTHETIC ASPECT
The different methods for the synthesis of sulphonamides have been
described in literature40-42
BIOLOGICAL IMPORTANCE
Many efforts have been undertaken to extend.The activity and reduce
toxicity of sulpha drugs. Monograms and review40-42 surveying various aspect
of sulpha drugs have been published.
W. Loh et al43 have prepared substituted sulphonamide derivatives (C)
which causes disappearance of tumor in 20-80% of  Leukemia bearing mice.
33
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 The antineoplastic activity of these compounds have been assessed in mice
bearing either Leukemia L1210 or P388
M. Kaldrikyan et al44 has synthesised N-(2-benzofuranyl methyl)-N-propyl-
4-propoxy benzen sulphonamide-(D) which reduced the blood glucose content
by 20%
O. Sharipov et al45 has studied the comparision of some sulphonamides
with their effect on blood coagulation in vitro. The seven sulphonamides tested,
streptoside was least active in delaying blood coagulation in vitro.
A.R. Parikh and Co workers synthesised sulphonamides having
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General structure of sulphonamides are as under
H.Parekh et al50 synthesised sulphonamides having-5-substituted 1,3,4-
oxadiazole moiety.
V.H. Shah et al synthesised sulphonamides having indole, benzothiazole51
fluchloralin52 2,4-dichlorophenoxyacetic acid53 dichloran54 moiety.
35
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General structure of sulphonamides are as under
THERAPEUTIC IMPORTANCE :
Sulphonamides and their derivatives showed well known therapeutic



















These valid observation prompted us to synthesis some new sulphonamide
derivatives bearing 1-aminoindan moiety in search of pharmaceutical agents
having better therapeutic activity, which have been described as under.
Section-I : Synthesis and biological screening of 1-N-aryl
sulphonamido indan
37
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-ARYL
SULPHONAMIDO INDAN
In view of procuring better therapeutic agents, the preparation of 1-N-aryl
sulphonamido indan of Type-(II) have been synthsised by the condensation of
1-aminoindan with aryl sulphonyl chloride.
The constitution of the products were supported by the elemental analysis,
IR, 1H NMR and Mass spectral studies. The products were tested for their
antimicrobial activity with MIC.
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Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; 4000-400 cm-1
(KBr disc)
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NMR  SPECTRAL STUDY OF 1-N-(5'-CARBOXY-2'-METHOXY
BENZENE SULPHONAMIDO) INDAN
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EXPERIMENTAL
SYNTHESIS OF 1-N-ARYL SULPHONAMIDO INDAN
(A) Synthesis of 1-N-(5'-Carboxy-2'-methoxy benzene sulphonamido)
indan
A mixture of 1-amino indan (1.33 gm, 0.01M) and 3-(chloro sulphonyl)
-4-methoxybenzoic acid (3.47 gm, 0.01M) in presence of  pyridine (5ml) was
refluxed. The reaction mixture was poured into crushed ice and filtered, washed
with water and recrystallized from methanol. Yield : 72.88 %, M.P : 114oC
(Found C:58.73, H: 4.87, N: 3.98 % ; C17 H17O5SN;  calcd. C: 58.78, H :
4.89; N : 4.06 %)
Similarly other sulphonamides have been synthesised. The physical
constants are recorded in Table No. 3.
(B) Biological Screening of 1-N-aryl sulphonamido indan
The antimicrobial testing was  carried out as describe in Part-I,
Section-I, Page : No. 26-29. The minimum inhibition concentration is
recorded in Table No. 4.
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(E)
 STUDIES ON 5-OXO-IMIDAZOLINES
INTRODUCTION
5-Oxo-imidazoline is a five membered heterocycle ring having two
nitrogen at 1 and 3-position and carbonyl group at 5-position-(E)
The discovery of the 2-substituted-5-oxo-imidazolines dates back to the
year 1888. When A. W. Hoffmann71 prepared 2-methyl-5-oxo-imidazolines
(lysidine) by heating N'-diacetyl ethylendiamine in a stream of dry hydrogen
chloride. A. Ledenburg72 has prepared the same compound by using two
equivalents of sodium acetate with one equivalent of ethylene diamine
dihydrochloride. Different methods for the synthesis of imidazolinones are
available in literature.73-76
MECHANISM :
In present study aromatic aldehyde were condensed with benzoyl glycine
in presence of anhydrous sodium acetate and acetic anhydride to get azlactones/
oxazolones.77
Azlactones reacts with variety of compounds such as water, alcohols, amines
and hydrogen halides. Amides of 2-aryl aminoacrylic acids obtained from the
49
Studies on some compounds of Medicinal Interest
condensation of azlactone and primary amine can be converted into
imidazolinones as shown in reactions.
The ring closure can be effected under a variety of conditions, substituted
anilides have been converted into imidazolinones by the reaction of POCl3. In
order to get variety of useful pharmacological important compounds, reaction
of azlactones have been extensively investigated with different type of
compounds such as alcohols78, thiophenols79, hydrazine hydrate80, aromatic
amino acids, phenyl hydrazine81 and ammonia.
SYNTHETIC ASPECT:
Reaction of azlactone with different aromatic amines have attracted a great
attention now a days because of the interesting nature of resulting compounds.
Their applications and their agrochemical and therapeutic activities. Different
methods have been documented for the synthesis of imidazolinones in literature 82-84
V. H. Shah et al have been synthesised imidazolinones having dichloran85
2,4-dichloro-6-amino sulpho phenoxy acetic acid86, fluchloralin87,
sulphonamido 4-(3H)-quinazolone moeities88.
50
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General structure of imidazoline are as under.
 THERAPEUTIC IMPORTANCE :
A. Persual of literature reveals that various imidazolinones have resulted in
many potential drugs are known to possess a broad therapeutic activities, which
are shown as under.
(a) Bactericidal activity89-92
(b) Anticonvulsant activity93-98
(c) Potent CNS depressant activity99-102
(d) Sedatives and hypnotic activity103
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(f) Hypotensive activity107-109
(g) Potent antiparkinson activity110-114
(h) Local anaesthetic activity115
(i) Antihistaminic activity116
(j) Antineoplastic activity117
(k) Antipyretic and analgesic activity118,119
(i) Antiinflammatory activity120-122
It was considered worthwhile to synthesis 5-oxo-imidazoline derivatives
which are as under.
SECTION-I : Synthesis and biological screening of 4-arylidene-1-
(Indan-1'-yl)-2-phenyl-5-oxo imidazolines
52
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 4-ARYLIDENE-1-
(INDAN-1'-YL)-2-PHENYL-5-OXO-IMIDAZOLINES
5-Oxo-imidazolines represent one of the most active classes of compounds
having a wide spectrum of biological activity. With an aim to getting better
therapeutic agents. 4-Arylidene -1-(indan-1'-yl)-2-phenyl-5-oxo- imidazolines of
Type-(III) have been synthsised by the condensation of 1-aminoindan with
different oxazolones. The oxazolones have been synthesised by Erlenmeyer
reaction.
The constitution of the products were supported by the elemental analysis,
IR, 1H NMR and Mass spectral studies. The products were tested for their
antimicrobial activity with  MIC.
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Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; 4000-400 cm-1
(KBr disc)
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Intrenal standard : TMS; solvent :DMSO-d6 : Instrument : BRUKER spectrometer
(500 MHz)
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(A) Synthesis of 4-(4"-methoxy benzylidine)-1-(indan-1'-yl)-2-phenyl-5-
oxo-imidazoline.
A mixture of 1-aminoindan (1.33 gm, 0.01M) and 4-(4'-methoxy
benzylidene)-2-phenyl-5-oxazolone  (2.78 gm, 0.01M) in pyridine (10 ml) was
refluxed for 4 hrs at 120oC. The reaction mixture was poured in to crushed ice,
filtered. The isolated product was crystalised from ethanol. Yield : 65.74 %,
M.P. : 164oC (Found: C:79.00; H: 5.54; N: 7.06 ; C25 H22O2N2  calcd.
C: 79.18; H : 5.58; N : 7.10 %)
Similarly other 5-oxo-imidazolines were synthesised and their physical
constants are recorded in Table No. 5.
(B) Biological Screening of 4-Arylidene-1-(indan-1'-yl)-2-phenyl-5-oxo-
imidazolines
The antimicrobial testing was carried out as described in Part-I, Section-I,
Page No. 26-29
The minimum inhibition concentration is recorded in Table No. 6.
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 STUDIES ON 4-THIAZOLIDINONES
INTRODUCTION
Thiazolidinones, which belong to an important group of heterocyclic com-
pounds have been extensively explored for their application in the field of medi-
cine. Thiazolidinones, with a carbonyl group at position 2(F), 4(G), on 5(H)
have been subjects of extensive study in the field of heterocyclic compounds.
Thiazolidinone with carbonyl group at 4-possition (G) substituent in 2,3-
and 5 possition may be varied but the greatest different in structure and properties
is exerted by the group attached to carbon atom at the 2-position and to N-atom
at the 3-position. V. H. Shah et al 123 have been synthesised 4-hiazolidinones
derivatives in thymol nucleus. C. Libermann et al124 have been reported studies
on 4-hiazolidinones.
The chemistry of 4-thiazolidinones was reviewed in depth by F. C. Brown125
in 1962 and G. R. Newkome and A. Nayak126 in 1977.
MECHANISM :
The reaction proceeds by the mercapto acetic acid upon the C=N group,
with the HS-CH2-COOH adding to the carbon atom followed by the capture of
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In the reaction, uncyclised intermidiate is formed in several cases. The
uncyclised product has been isolated127, phosphorous pentoxide in dioxane
was used for subsequent cyclisation of certain uncyclised products128. In many
instance 4-thiazolidinones can conveniently be prepared by refluxing the mixture
of the thioglycolic acid and schiff's bases in benzene129, dry ether130 or
ethanol131.
The nucleophilic attach of mercapto acetic acid anion on carbon of
azomethine, which has possitive character while nitrogen has negative character
is evidenced, simultaneously removal of water  formed in reaction, helps in
condensation and determination of the reaction time.
SYNTHETIC ASPECT :
4-Thiazolidinones are synthesised either by cyclisation of acyclic compounds
or by interconversion among appropriately substituted thiazolidinone derivatives.
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The substituted -mercapto alkanoic acid react conveniently with schiff's
bases to give a variety of 2-substituted-4-thiazolidinones132-134
THERAPEUTIC IMPORTANCE :
4-Thiazolidinones substituted at 2- and 3-position showed a wide variety of
biological activity. The frequent ocurrence of group-NH-C-NH - or its tautomer


















K. Mogliaiah and Co-workers162,163 isolated some 4-thiazolidinones
derivatives and tested their antibacterial activity. H.Y. Hassan et al.164 has
prepared 2-amino 4-thiazolidinones, which have been found to possess antimicrobial
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R. S. Lodhi and co-worker166 have been synthesised and studied anti-
microbial, anti-inflammatory and analgesic activity of 4-thiazolidinone
derivatives (J).
G. Bhawana et al167 have been synthesised thiazolidinone derivatives and
compared their antiinflammatory potency, ulcerogenic liability, cardiovascular
and CNS effect. R. P. Pawar and co-workers168 reported synthesis and in vitro
antibacterial activity of some 4-thiazolidinone derivatives. G. G. Bhatt169 have
been reported 4-thiazolidinone derivatives and aveluated their activity. A. J. Baxi
et al170 have been synthesised 4-thiazolidinone derivatives and also evaluated
antimicrobial activity.
Morever Albuquerque and co-workers171 have prepared 4-thiazolidinones
which show antidiabetic and antiinflammatory activity. Tagami and co-worker172
have synthesised 4-thiazolidinone derivatives as allergy inhibitor. M. Siddique  et
al173 have prepared substituted thiazolidinones and reported their antibacterial,
antifungal, antithyroid and amoebicidal properties (K).
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(L)
68
H. S. Joshi et al175 have synthesised microwave assisted 4-thiazolidinones
and reported as biological active agents.
In view of getting to synthesis some new 4-thiazolidinone derivatives and
evaluated their antimicribial activity with MIC, which have been described as
under.
SECTION-I : Synthesis and biological screening of 1-substituted
benzylidene aminoindan.
SECTION-II : Synthesis and biological screening of 2-aryl-3-indanyl-
5H-4-thiazolidinones.
SECTION-III: Synthesis and biological screening of 2-aryl-3-indanyl-
5-carboxy methyl-4-thiazolidinones.
SECTION-IV: Synthesis and biological screening of 1-substituted
benzyl aminoindan.
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-SUBSTITUTED
BEZYLIDENE AMINOINDAN
Recently much interest has been focused on the synthesis and biodynamic
activities of schiff's bases with a view to obtained compounds having better
therapeutic activity. 1-substituted benzelidene aminoindan have been synthesised
by the condensation of 1-aminoindan with different aromatic aldehyde.
The constitution of the products were supported by the elemental analysis,
IR, 1H NMR and Mass spectral studies. The products were tested for their
antimicrobial activity with  MIC.
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NMR SPECTRAL STUDY OF 1-(4'-METHOXY BENZYLIDENE) AMINOINDAN










































































































































































































































































































































































































































































Type : (IV) R = Aryl
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EXPERIMENTAL
SYNTHESIS OF 1-SUBSTITUTED BENZYLIDENE AMINOINDAN
(A) Synthesis of 1-(4'-methoxy benzylidene) aminoindan
A mixture of 1-aminoindan (1.33 gm, 0.01 M) and 4-methoxy
benzaldehyde (1.30 gm, 0.01M) and ethanol  (25 ml) was heated under refluxed
in a water bath for 8 hours. The reaction mixture was poured into crushed ice,
filtered, dried and crystallised from ethanol. yield : 79.68 %, M.P : 100oC
(Found C:81.23; H: 6.71; N: 5.52 ; C17 H17ON calcd. C: 81.27; H : 6.77;
N : 5.58 %)
Similarly other schiff's bases have been synthesized and their physical
constants are recorded in in Table No. 7
(B) Biological Screening of 1-substituted benzylidene aminoindan
The antimicrobial testing was  carried out as describe in Part-I,
Section-I, Page : No. 26-29.
The minimum inhibition concentration is recorded in Table No. 8.
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SECTION - II
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-ARYL-3-
INDANYL-5-(H)-4-THIAZOLIDINONES
Taking into consideration of wide range of therapeutic activity
of 4-thizolidinone derivatives, with a view of synthesis of 2-aryl-3-indanyl-5-(H)-
4-thizolidinones have been synthesised by the condensation of-1-substituted
benzylidene aminoindan with thioglycolic acid.
The constitution of the products were supported by the elemental analysis,
IR, 1H NMR and Mass spectral studies. The products were tested for their
antimicrobial activity with  MIC.
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Intrenal standard : TMS; solvent :CDCl3 : Instrument : BRUKER spectrometer
(500 MHz)
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Type : (V) R = Aryl
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EXPERIMENTAL
SYNTHESIS OF 2-ARYL-3-INDANYL-5-(H)-4-THIAZOLIDINONES
(A) Synthesis of 1-(4'-methoxy benzylidene) aminoindan
See part-IV, Section - I, Page No. 76.
(B) Synthesis of  2-(4'-methoxy phenyl)-3-indanyl-5-(H)-4-thiazolidinone
In a 250 ml R.B.F. 1-(4'-methoxy benzylidene) aminoindan (2.51 g, 0.01 M)
taken in benzene. Dean stark apparatus was attached to it and thioglycolic acid
(0.92g, 0.01 M) in benzene was added slowly. Then it was refluxed for 15 hrs,
during the course of the reaction the water was removed continuously. The
benzene was distilled out to get the thiazolidinone. The solid product was
filtered, dried and recrystallized from absolute alcohol. Yield : 68.06% ; m.p.:
54oC (Found : C:70.04; H: 5.79; N: 4.28 ; C19 H19O2NS calcd. C: 70.15;
H:5.84; N : 4.31 %)
Similarly other 4-thiazolidinones have been synthesized and their physical
constants are recorded in Table No. 9.
(C) Biological Screening of 2-aryl -3-indanyl-5-(H)-4-thiazolidinones
The antimicrobial testing was  carried out as describe in Part-I,
Section-I, Page : No. 26-29.
The minimum inhibition concentration is recorded in Table No. 10.
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SECTION - III
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-ARYL-3-
INDANYL -5-CARBOXYMETHYL-4-THIAZOLIDINONES
4-Thiazolidinones derivatives represent one of the important classes of
compounds having a broad spectrum of biological activities, with a view of
getting better therapeutic agents, the synthesis of 2-aryl-3-indanyl-5-carborxy
methyl-4-thiazolidinones of Ttype -(VI) have been synthesised by the reaction of
1-substituted benzylidene aminoindan with thiomalic acid.
The constitution of the products were supported by the elemental analysis,
IR, 1H NMR and Mass spectral studies. The products were tested for their
antimicrobial activity with  MIC.
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IR SPECTRAL STUDY OF 2-(4'-HYDROXY PHENYL) - 3 - INDANYL-








































































Intrenal standard : TMS; solvent :DMSO-d6 : Instrument : BRUKER spectrometer
(400 MHz)
NMR SPECTRAL STUDY OF 2-(4'-HYDROXY PHENYL) - 3 -
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EXPERIMENTAL
SYNTHESIS OF 2-ARYL-3-INDANYL-5-CARBOXY METHYL-4-
THIAZOLIDINONES
(A) Synthesis of 1-(4'-methoxy banzylidene) aminoindan
See part-IV,  Section - I, Page No. 76.
(B) Synthesis of  2-(4'-methoxy phenyl)-3-indanyl-5-carboxy methyl-4-
thiazolidinone
In a 250 ml R.B.F. 1-(4'-methoxy benzylidene) aminoindan (2.51 g, 0.01 M)
in benzene was taken,Dean stark apparatus was attached to it and thiomalic
acid (1.50g, 0.01 M) in benzene was added slowly. Then it was refluxed for 15
hrs, during the course of the reaction the water was removed continuously.
The benzene was distilled out to get the thiazolidinone. The solid product was
filtered, dried and crystallized from absolute alcohol. Yield : 89.13%; M.P.
80oC (Found  C:65.76;  H: 5.43; N: 3.58 % ; C21H21O4NS calcd. C: 65.80;
H:5.48; N:3.65 %)
Similarly other 4-thiazolidinones have been synthesized and their physical
constants are recorded in Table No. 11.
(C) Biological screening of 2-aryl-3-indanyl-5- carboxy-4-thiazolidinones
The antimicrobial testing was  carried out as describe in Part-I,
Section-I, Page : No. 26-29.
The minimum inhibition concentration is recorded in Table No.  12
96
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SECTION - IV
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-SUBSTITUTED
BENZYL AMINOINDAN
In a view of procuring better therapeutic agents to synthesis 1-substituted
benzyl aminoindan of Type-(VII)  by the reaction of 1-substituted benzylidene
aminoindan of Type (IV) with anhydrous NaBH4
The constitution of the products were supported by the elemental analysis,
IR, 1H NMR and Mass spectral studies. The products were tested for their
antimicrobial activity with  MIC.
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Intrenal standard : TMS; solvent : MeOD : Instrument : BRUKER spectrometer
(500 MHz)














































































































































































































































































































































































































Type : (VII) R = Aryl
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EXPERIMENTAL
SYNTHESIS OF 1-SUBSTITUTED BENZYLAMINO INDAN
(A) Synthesis of 1-(4'-methoxy benzylidene) aminoindan
See part-IV, Section - I, Page No.76.
(B) Synthesis of  1-(4'-methoxy benzylamino) indan
A mixture of 1-(4'-methoxy benzylidene) aminoindan (2.51 gm, 0.01 M),
NaBH4 (0.38 g, 0.01 M) and methanol (15 ml) was stirring for 10 hrs. and then
extracted with Dichloromethan (3 x 50 ml). After evaporation of  Dichloromethan
the product was obtained as light yellow oily liquid. Yield : 63.17 % ; B.P.:
116oC (Found : C:80.56; H : 7.48; N:5.48   C17 H19ON calcd. C: 80.63; H :
7.51; N : 5.53 %)
Similarly other 1-substituted benzylamino indan of Type- (VII) have been
synthesised and their physical constants are recorded in Table No. 13.
(C) Biological Screening of 1-substituted banzylaminoindans
The antimicrobial testing was  carried out as describe in Part-I,
Section-I, Page : No. 26-29.
The minimum inhibition concentration is recorded in Table No.14.
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 STUDIES ON 2 - AZETIDINONES
INTRODUCTION
The four membered -lactam (2-azetidinone) ring system (M) has for many
years been of great practical significance as the centre of reactivity of penicillins
(N) and Cephalosporin (O).
Much efforts has been put into the synthesise of simple  -lactams for
testing as antibiotics, anti-depressants, sedatives176 etc. Synthesis of
2-azitidinones have been extensively studied by Sheeham and Corey.177
More recently other aspects of synthesis have been reviewed178,179. Different
methods of preparation have been cited literature180-187. A.J. Baxi et. al.188
have been synthesised 2-azetidinone derivatives and also evaluted antimicrobial
screening,
MECHANISM :
Synthesis of -lactam consists of the addition of C-N and   =O component
to form a ring substituted acetyl chloride with electron withdrawing substituents
and atleast one hydrogen at -carbon add to imines in the presence of amine
bases189. The mechanism take place by nonconcerted cycloaddition reaction
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The reaction may be experimented in many cases by treating a mixture of
the imine and dichloro acetic acid with POCl3 or POBr3190-191. It has been
observed that the acid chloride is formed as an intermediate through the
phosphorus halide participate as an electrophillic catalyst as shown in following
scheme (Q).
Cycloaddition of diphenylketone to a performed imine192 also forms
-lactam.
THERAPEUTIC IMPORTANCE:
-Lactam drugs are still the most widely prescribed antibiotics used in
medicines193 2-Azetidinone derivatives possess wide therapeutic activity viz.
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also effective on the central nervous system196. A large number of 3-chloro
monocyclic -lactams have been prepared by the cycloaddition of ,-
disubstituted enamines with aryl isothiocyanates which possess a powerful anti-
bacterial  activity197.
A series of 7--(2-amino pyrimidinyl)-2-oxyimino acetamido-cephalosporins
have been prepared by J. Goto et al198 as useful antibiotics. Penicillins of type
(R) and their corresponding penicillins gave antibacterial activity.
Sunakawa et al199 have been synthesised Several alkyl, alkenyl, alkonyl,
2-azetidinons and 3-alkyl-4-halomethyl/arylmethyl-2-azetidinones. K. Akiba200
have been reported 4-(trifluoromethyl)-2-azetidinone derivatives. K. Chikra et al
201 and G. S. Bisacchi et al 202 prepared intermediates for antibiotics.
M. Sendai and co-workers203 have prepared 2-azetidinones of type (S)
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2-Azetidinone derivatives have been reported as antiparkinson, antibacterial
and antifungal204-211 antiinflammatory212-214 hypochloresterolimic215 and
antimicrobial agents.
V. Jayamma and co-workers217 have prepared some new derivatives of
2-azetidinones and tested their antimicrobial activity. S. Giri et al218 have
synthesised some l-[5'-aryl-1',3',4'-thiadiazol-2'-yl]-3-chloro-4-substituted
2-azetidinones  as potential fungicides.
Morever, Saito et.al.219 have synthesized some new azetidinones as a
carbapenem antibiotics. V. H. Shah et al220 have reported azetidinones
derivatives as antimicrobial and antitubercular agents. Khalafallah et.al221 have
synthesised some new azetidinone derivatives and screening their antimicrobial
activity. J. B. Doherty222 and co-workers have prepared some new azetidinones
and reported their antiinflammatory activity.
R.H.Udupi et al223 synthesised some new azetidinone molecules which
shows good antiinflammatory, antitubercular, bactericidal and fungicidal
activity. Vaccaro, Wayne D. and Co-workers224 prepared some novel azetidinone
derivatives as cholesterol absorption inhibitors, Mckittrick Brain A. and co-work-
ers 225 have prepared some new azetidinones display potent cholesterol absorp-
tion inhibitory activity.
H. H. Parekh et al226 have synthesised 2-azetidinones as antimicrobial agent (T).
(T)
113
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H. S. Joshi et. al. 227 have synthesised some 2-azetidinone derivatives as
antitubercular and antimicrobial agent (U).
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-N-INDANYL-4-
ARYL-3-CHLORO-2-AZETIDINONES
In view of procuring better therapeutic activity of 2-azetidinone derivatives,
the preparation of 1-N- indanyl-4-aryl-3-chloro-2- azetidinones of  Type (VIII)
have been synthesized by the condensation of 1-substituted benzylidene amino
indan of Type-(IV) with chloroacetyl chloride in presence of triethyl amine as a
catalyst.
The constitution of the products were supported by the elemental analysis,
IR, 1H NMR and Mass spectral studies. The products were tested for their
antimicrobial activity with  MIC.
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Intrenal standard : TMS; solvent :DMSO-d6 : Instrument : BRUKER spectrometer
(500 MHz)
































































































































































































































































































































































































































































Type : (VIII) R = Aryl
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EXPERIMENTAL
SYNTHESIS OF 1-N-INDANYL-4-ARYL-3-CHLORO-2-AZETIDINONES
(A) Synthesis of 1-(4'-methoxy banzylidene) aminoindan
See part-IV, Section - I, Page No. 76.
(B) Synthesis of  1-N-indanyl-4-(4'-methoxy phenyl) - 3-chloro - 2 -
azetidinone.
A mixture of 1-(4'-methoxy benzylidene) aminoindan (2.51 gm, 0.01 M),
chloroacetyl chloride (1.2 ml, 0.01 M) and triethylamine (1 ml) in benzene shake
vigouresly then after refluxed for 5-6 hrs. The triethyl amine hydrochloride salt
formed was removed and the benzene was distilled out to get product. The solid
product was filtered, dried and crystallized from ethanol. Yield : 69.70 % ; M.P.:
146oC (Found : C:69.58; H: 5.42; N: 4.21; C19H18O2N Cl calcd. C: 69.62;
H: 5.49; N : 4.27 %)
Similarly other azetidinones have been synthesized and their physical
constants are recorded in Table No.15
(C) Biological Screening of 1-N-indanyl-4-aryl-3-chloro-2-azetidinones
The antimicrobial testing was  carried out as describe in Part-I,
Section-I, Page : No. 26-29.
The minimum inhibition concentration is recorded in Table No. 16.
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Studies on some compounds of Medicinal Interest
STUDIES ON CHALCONES
INTRODUCTION
The chemistry of chalcones (V) have generated intensive scientific     studies
throughout the world specially interesting for their biological and industrial
applications. Chalcones are coloured compounds because of the presence of
the chromophore, auxochromes. They are known as benzalacetophenones or
benzylidene acetophenones. S.V. Kostanecki and J. Tambor228 gave the name
"Chalcone".
Chalcone are characterised by their possession of a structure in which
two aromatic rings A and B are linked by an aliphatic three carbon chain.
The alternative names given to chlacones are phenyl styryl ketones,
benzalacetophenones. -phenyl acrylphenone, -oxo---diphenyl--propylene
and -phenyl--benzoethylene.
SYNTHTIC ASPECT:
A considerable variety of methods are available for the synthesis of
chalcones. The most convenient method is one that involves the
Claisen-Schmidt condensation of equimolar quantities of an aryl methyl ketones
with aryl aldehyde in presence of alcoholic alkali.229
(V)
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Several condensing agents used are alkali of different strength230,231,
hydrogen chloride 232,233 ,Phosphorous oxychloride 234, Piperidine235,
anhydrous Aluminium choride236, Boron trifluoride237, aqueous solution
of  borax238, amino acid239 and perchloric acid240 etc.
MECHANISM:
Chalcone formation proceeds through aldol type of condensation and
the process is catalysed by the presence of alkali241, following steps of the
reaction mechanism are as under.
The intermediate Aldol type of products formed readily undergoes
dehydration even under mild condition, particularly when R and R' are aryl
groups.
REACTIVITY OF CHALCONES:
The chalcone have been found to be useful for the synthesis of variety
of heterocyclic compounds are as under.
(a) Pyrazolines242 and its derivatives can be prepared by the condensation
of chalcones with hydrazine hydrate and acetic acid.
(b) Chalcones on condensation with malononitrile and ammonium acetate
yields 2-amino-3-cyano pyridines243.
(c) Isoxazoles244 can be prepared by the treatment of chalcones with
127
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hydroxylamine hydrochloride and sodium acetate.
(d) Chalcone on condensation with malononitrile in pyridine forms 2-amino
3-cyanopyrans.245
(e) Chalcones on treatment with urea in presence of alkali affords 2-oxo
Pyrimidines246
(f) Chalcones on reaction with thiourea in presence of alkali/acid yields 2-
thiopyrimidines.247
(g) Chalcones on treatment with guanidine hydrochloride in presence of
alkali affords 2-amino pyrimidines.248
(h) Chalcones react with P2S5 yielding 2-isothiazolines.249
(i) Chalcones with sodium nitrile in presence of glacial acetic acid in
ethanol produces 2-(H)-pyrimidines.250
(j) Chalcones with monoethanolamine in ethanol gives 1,4-oxazipines.251
(k) Chalcones with 2-amino thiophenol in acetic acid produces 1,5-
thiazepines.252
(l) Chalcones on reaction with semicarbazide hydrochloride in ethanol
affords 1-caroxamide pyrazolines.253
(m) Chalcones on reaction with 2-aminopyrimidine in glacial acetic acid
affords pyrido pyrimidines.254
(n) Oxiran255 can be prepared by the reaction of chalcone with H2O2 in
basic media.
(o) Cyanopyridone256 derivatives can be prepared by the condensation of
Chalcone with ethylcyanoacetate.
(p) Chalcones gives imine derivatives with amine in presence of sulphuric
acid as a catalyst.257
(q) Chalcone on reaction with barbituric acid gave barbitone derivatives.258
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THERAPEUTIC INTEREST:
Chalcones are potential biocides, some naturally occuring antibiotics
and aminochalcones probably own their biological activity to the presence of














Moreover, synthesis and antibacterial activity of substituted chalcone
derivatives have been reported by S.R. Modi et al277. A. Attia278 and V. R.
Mudalir et al279 have prepared phenoxy chalcones and observed their
insecticidal activity. Kammei et al280 have been synthesised substituted
chalcones and evaluated their insecticidal activity. R. De vincenzo et al 281
and Han et al282 have synthesised chalcone derivatives and reported their
anti-inflammatory activity. Okuyana et al283 have been synthesised chalcone
derivatives and reported reductase inhibitor activity. A. Tsotitus et al284
reported antitumor and antifungal activity of chalcone derivatives.
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P. N. Sharma and Shrenivasulu285 synthesised substituted chalcones and
evaluated their antifeedant activity.
Ezio Bombardelli et al286. have demonstrated that chalcone possess a
valuable antiproliferation activity both on sensitive cancereous cell and on cell
which are resistant to common chemotherapeutic drugs. S.Elichi et al287 have
been patented chalcones for their use for treatment of glaucoma. B. B. kailashnikov
et al288 and S. Santoshi et al289 showed antifungal activity.  P. Walavalker et al 290
showed aldose reductase inhibitor. O. tory et al291 evaluated anticancer activity.
J. R. Dimmock. et al292 and T.M. Abdelr rahman293 evaluated antimicrobial
activity of chalcones.
Recently, Ni Liming et al.294 have synthesised chalcones and screened for
their  antiinflammatory and cardiovascular activity. Kumar Srinivas et al295 have
synthesised chalcones as an antitumor agent. Ko Horng Huey et al296 have
prepared chalcones as antiinflammatory agent. Nakahara Kazuhiko et al297 have
synthesised chalcones as carcinogen inhibitors. Lin Yah meei et al298 have
been  synthesised by chalcones derivatives and evaluated their antitubercular
activity.
B. R. Das et al299 have synthesised chalcones and reported their larvicidal
properties. Kirm Min Young et al300 have synthesised chalcones and tested for
their matrix metalloproteinase inhibitor activity.
Liu Mei et al301 have been prepared chalcones and evaluated  antimalarial
activity. O. veronika et al302 have synthesised chalcones and screened as
cardiovascular agent.
Moreover, it has been found that chalcone derivatives possesses nitric
oxide inhibitor303,304 and anti-HIV305,306 activities.
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Chalcone derivatives are important raw materials to prepare different
heterocyclic compounds like isoxazoles, pyrazolines,pyrimidines, pyridines,
cyanopyrans etc. and chalcones also gave better therapeutic activity, with a
view of getting to synthesis chalcones, which are described are as under.
SECTION : I SYNTHESIS AND BIOLOGICAL SCREENING
OF 11-{4'-[(3"-ARYL) -2"- PROPENE-1"-ONE]-
PHENOXY} DIBENZ [b,f] THIAZEPINES
131
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SECTION - I
  SYNTHESIS AND BIOLOGICAL SCREENING OF 11-{4'-[(3"-ARYL)
  -2"- PROPENE-1"-ONE] -PHENOXY} DIBENZO [b,f] THIAZEPINES
Recently much interest has been focused on the synthesis and biodynamic
activities of chalcones and it is a good synthon for various heterocyclic rings.
with an aim to getting better therapeutic agents, 11-{4'-[(3"-aryl)-2" propene-1"-
one]-phenoxy} dibenzo [b,f] thiazepines have been synthesised by the
condensation of 11-{4' acetyl phenoxy) dibenzo [b,f] thiazepine with different
aromatic aldehyde in presence of aq.alkali. The latter was 11-(4'-acetyl phenoxy)
dibenzo [b,f] thiazepine have been synthesised by the condensation of 11-chloro
dibenzo [b,f] thiazepine with 4-aminoacetophenone.
The constitution of the products were supported by the elemental analysis,
IR, 1H NMR and Mass spectral studies. The products were tested for their
antimicrobial activity with  MIC.
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IR SPECTRAL STUDY OF 11-{4'-[3"-(4'"-METHOXY PHENYL)-2"-












































Intrenal standard : TMS; solvent :DMSO-d6 : Instrument : BRUKER spectrometer
(500 MHz)
NMR SPECTRAL STUDY OF 11-{4'-[3"-(4"'-METHOXY PHENYL)-






















































































































































































































































































































































































































































































Type : (IX) R = Aryl
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(A) Synthesis of 11-(4'- acetyl phenoxy) dibenzo [b,f] thiazepine
A mixture of 11- chloro dibenzo [b,f] thiazepine  (2.45 g, 0.01 M) in
acetonitrile (25ml) and potassium carbonate (4 gm) was refluxed on a water bath
at 80-85oC for 24 hrs. The product was cooled, poured into crushed ice, filtered,
dried and crystallized from ethanol. Yield : 76.85 % ; M.P.: 160oC (Found :
C:72.98, H: 4.28; N : 4.01 ; C21H15O2NS calcd. C: 73.04; H : 4.35; N : 4.06 %)
(B) Synthesis of 11-{4'-[3''-(4"'-methoxy phenyl)-2"-propene-1"-one]-
phenoxy dibenzo [b,f] thiazepine
A mixture of 11-(4'-acetyl phenoxy) dibenzo [b,f] thiazepine (3.45 g, 0.01M)
and 4-methoxy benzaldehyde (1.36 g, 0.01 M) in methanol 25 ml and 40%
NaOH solution (25 ml) was stirring 24 hrs then after refluxed on a water bath for
8 hrs. The contents were poured into crushed ice, acidified, filtered, dried and
crystallized from ethanol.  Yield : 88.43%, M.P.: 212oC (Found : C:75.13; H:4.50;
N:3.00; C29 H21O3 NS calcd. : C:75.16; H:4.54; N: 3.02%)
Similarly other chalcones have been synthesized and their physical
constants are recorded in Table No. 17
(C) Biological Screening  of 11-{4'-[(3"-aryl)-2"-propene-1"-one]-
phenoxy} dibenzo [b,f] thiazepine
The antimicrobial testing was  carried out as describe in Part-I,
Section-I, Page : No. 26-29.
The minimum inhibition concentration is recorded in Table No. 18
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STUDIES ON PYRAZOLINES
INTRODUCTION
Amongst nitrogen containing five membered heterocycles, pyrazolines (W)
have proved to be the most useful frame work for biological activities, pyrazolines
have attracted attention of medicinal chemistry for both with regard to heterocyclic
chemistry and the pharmacological activities associated with them. J. Elgureo
et al307 and R. S. Theobald308 reviewed the chemistry of pyrazolines, which
have been studied extensively for their industrial applications.
SYNTHETIC ASPECT :
Different methods for the preparation of 2-pyrazoline derivatives
documented in literature are as follows.
(1) 2-pyrazolines can be constructed by the cyclocondensntion of chalcones
with hydrazine hydrate.309
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(3) 2-Pyrazolines can be synthesised by the cycloaddition of diazomethane
to substituted chalcone.311
(4) Dipolar cycloaddition of nitrilimines of dimethyl fumarate fumaronitrile
and the N-aryl maleimides yields the corresponding pyrazolines.312
(5) Epoxidation of chalcones have epoxy ketones which reacted with
hydrazine and phenyl hydrazine to give pyrazolines.313
Further more, B. Gyassi et al314 investigated the one pot synthesis of
some pyrazolines in dry media under microwave irradiation. S. Paul et al315
and A. Dandia et al316 have also described the microwave assisted synthesis
of 2-pyrazolines.
MECHANISM:
The following mechanism seems to be operable for the condensation of
chalcones with hydrazine hydrate.317
Nucleophilic attack by hydrazine at the -carbon of the 
unsaturated carbonyl system forms species (II) in which the-ve charge is
mainly accomodated of the electro nagative oxygen atom.
144
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Proton transfer from the nitrogen to -ve oxygen produces an
intermediate enol which simultaniously ketonise to ketoamine (III). Another
intramolecular nucleophilic attack by the primary amino group of ketoamine
on its carbonyl carbon followed by proton transfer from nitrogen to oxygen
leads ultimately to amine (IV). The later with a hydroxy group and amino
group on the carbon lose water moleculer to yield the pyrazolines.
THERAPEUTIC IMPORTANCE:
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S. S. Sonarc et al.338 have synthesised-3-(2-acetoxy-4-methoxy
phenyl)-5-(substituted phenyl)-pyrazolines (X) and tested their antimicrobial
activity.
Moreover, T. M. Stivenson et al339  have also investigated N-substituted
pyrazoline and evaluated insecticidal activity. T. Katsuhori340 have patented
pyrazoline derivatives as herbicides and K. Johannes et al341 reported
insecticidal activity of pyrazolines. Z. Moritaz and S. Hadol342 to
investigated a semi emperial molecular orbital study on the reaction of
aminopyrazolinyl azodye with singlet molecular oxygen.
M. K. Shivnanda and co-worker343 have prepared pyrazolines and
reported their antibacterial activity. B. Shivarama Holla et al344,345 have
synthesised pyrazolines as antibacterial agent. S. P. Hiremath et al346 have
synthesised pyrazolines as analgesic, antiinflammatory and antimicrobial agents.
V. Malhotra et al347 have synthesised new pyrazolines as a cardiovascular
agent.
Ji-Inkim Almstead et al348 have prepared pyrazolines as vascularization
agent.Guniz Kucukguzel et al349 have synthesised pyrazolines as a
antimicrobial and anticonvulsant agents.
(X)
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T. Z. Gulhan and co-workers350 have prepared pyrazolines as a
hypotensive agent. S. Sharma et al351  have synthesised pyrazolines and
tested their antiinflammatory activity. Ashok Kumar et al352 have synthesised
pyrazolines as anticonvulsant agent. B. Jayshankara et al353 have synthesised
pyrazolines and screened for their epilepsy activity.
In view of therapeutic activities shown by pyrazolines, it was
contempted to synthesis some new pyrazolines, which have been described
as under.
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 11-{4'-[(5"-ARYL)-
4"-5"-DIHYDRO-1"-(H)- PYRAZOL-3"-YL]-PHENOXY} DIBENZO
[b,f] THIAZEPINES
Pyrazoline derivatives posess broad spectum of pharmacological activity
which are reflected by their use as analgesic, antiinflammatory, anticonvulsant,
antimicrobial and antipyretic agent, prometed by above facts to synthesis
11-{4'-[(5"-aryl)-4"-5"-dihydro-1"-(H)- pyrazol-3"-yl]-phenoxy} dibenzo [b,f]
thiazepines of Type-(X) have been synthesised by the condensation between
11-{4'-[(3"-aryl)-2"-propene-1"-one]-phenoxy} dibenzo [b,f] thiazepines with
hydrazine hydrate.
The constitution of the products were supported by the elemental analysis,
IR, 1H NMR and Mass spectral studies. The products were tested for their
antimicrobial activity with  MIC.
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Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; 4000-400 cm-1
(KBr disc)







































































































Intrenal standard : TMS; solvent :DMSO-d6 : Instrument : BRUKER spectrometer
(500 MHz)
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EXPERIMENTAL
SYNTHESIS OF 11-{4'-[(5"-ARYL)-4-"-5"-DIHYDRO-1"-(H)-
PYRAZOL-3"-YL]-PHENOXY} DIBENZO [b,f] THIAZEPINES
(A) Synthesis of 11-(4'-acetyl phenoxy) dibenzo [b,f] thiazepine
See Part - VI, Section - I, Page No. 139.
(B) Synthesis of 11-{4'-[3"-(4'''-methoxy phenyl)-2"- propene -1"-one]-
phenoxy} dibenzo [b,f] thiazepine
See part - VI, Sextion-I, Page No. 139.
(c) Synthesis of 11-{4'-[5"-(4"'-methoxy phenyl)- 4"-5"-dihydro-1"- (H)-
pyrazol-3"-yl]-phenoxy} dibenzo [b,f] thiazepine
A mixture of 11-{4'-[3"-(4"'-methoxy phenyl)- 2"propene-1"-one] phenoxy}
dibenzo [b,f] thiazepine (4.63 gm, 0.01 M), hydrazine hydrate (1.0 ml) in metha-
nol (15 ml) was refluxed for 12 hrs. The reaction mixture was poured into crushed
ice, filtered, dried and crystallized from dioxan.Yield : 69.88 % ; M.P.: 114oC
(Found : C:72.93; H: 4.81; N : 8.76 ; C29H23O2N3S calcd. C: 72.96; H : 4.82; N
: 8.80 %)
Similarly other pyrazolines were synthesized and their physical constants
are recorded in Table No. 19.
(D) Biological screening of 11-{4'-[(5"-aryl)-4"-5"-dihydro-1"-(H)-pyrazol
-3"-yl]-phenoxy} dibenzo [b,f] thiazepine
The antimicrobial testing was carried out as describe in Part-I,
Section-I, Page : No. 26-29.
The minimum inhibition concentration is recorded in Table No. 20.
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STUDIES ON PYRIMIDINES
INTRODUCTION
Pyrimidine derivatives occur in natural products 354  like nucleic acid
and vitamin-B have remarkable pharmaceutical importance because of thier
biological355-358 several analogous of nucleic acids have been used as
compound that interfere with the synthesis and functioning of nucleic acids
and example is fluorouracil which has been used in cancer treatment.
Pyrimidines are among those molecules that make life possible as being same
of the building blocks of DNA and RNA.
Some pyrimidines of physiologically as well as pharmacologically
importance are as under : e.g. cytosine, beclmeihrin (Y), blasticidin (Z).
Synthetic pyrimidine derivatives contribute much to the searchable
literature of pyrimidine derivtives, in huge libraries owing to their wide
applicability in different fields.
SYNTHETIC ASPECT:
Different methods for the synthesis of pyrimidine have been cited in the
literature.359
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MECHANISM :
The reaction of - unsaturated system with urea to the formation of
4-oxo-pyrimidine by 1,2 and 1,4-michal addition.
160
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THERAPEUTIC IMPORTANCE
Pyrimidine derivatives have proven to be of great importance in
exhibiting and enhancing the biological activities such as.
(a) Antitumor 361
(b) Carcinostatic 362










Moreover, L. V. Azarayan et al.385 have synthesised pyrimidine diones
as antitumor agent. V. P. Krivongov and co-worker 386 have synthesised
pyrimidinone derivatives possessing immunotropic and antiinflammatory
activitiy. M. Refai and co-worker 387 have prepared some new pyrimidine
derivatives showed moderate activity against the growth of Bacillus substilis,
Staphylococus aureus and Aspergillus niger. A. Kofies et. al.388 have
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K. Mogilaiah 389 have prepared spiropyrimidinones as antibacterial
agents. M. wilhelm390 have synthesised pyrimidinones as herbicidal agents.
C. D. Timothy and co-worker391 have suggested imidazolyl
pyrimidinones as antiviral. T. Nagamatsu et al392  have prepared some new
triazolo [3,4-c] pyrimidine as xanthin oxidase inhibitors. A. Roland et al393
have prepared oxazolyl uracil as herbicidal and insecticidal. M. M. Yari and
co-worker 394 have investigated the pyrimidinone derivatives which possess
calcium antagonist activity.
M. A. Bruce and co-worker 395 prepared The dihydropyrimidinones as
NPY antagonist.
D. R. Sidler396 have reported pyrimidinone derivatives, useful as an
-adrenergic receptor antagonist.
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Mona Mahram and co-worker 397  have synthesied pyrimidine
derivatives as potent antimicrobial and antitumor agents.
K.A. Gupta and co-worker398  have prepared 2,6-disubstituted
pyrimidinones as CNS agent.
Pyrimidinone derivatives 399,400 have found to be calcium channel
blocker
M.M.Barbuliene et. al.401 have synthesised pyrimidinones as antiinflammatory
agent.
Recently. Amjad Ali et. al.402 have synthesised new fused pyrimidinones
as antimicrobial agents. Abd El-Galil et. al.403 have synthesised pyrimidine as
163
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androgenic, anabolic and antiinflammatory agents. Martin Bolli et al404 have
synthesised pyrimidines as endothelin receptor antagonists. G. Z. Hang et. al.
405 have synthesised and screened for their leukocyte functions inhibitor
activity. Yamamoto et al406 have synthesised pyrimidines and tested their
hyderproliferative disorder activity. Adenosine receptor antagonist pyrimidinones
have been prepared by Tsytsumi Hideo et. al. 407
SECTION - I SYNTHESIS AND BIOLOGICAL SCREENING OF
11-{4'-[(6"-ARYL)-2"-MERCAPTO-3",4"-DIHYDRO
PYRIMIDINE 4-"-YL]-PHENOXY} DIBENZO [b,f]
THIAZEPINES
164
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 11-{4'-[(6"-ARYL)-
2"-MERCAPTO-3",4"-DIHYDRO PYRIMIDINE 4-"-YL]-PHENOXY}
DIBENZO [b,f] THIAZEPINES
Looking to the interesting pharmacological and agricultural activity of
pyrimidine ring system, it was considered worthwhile to synthesise compounds
bearing phenoxy dibenzo [b,f] thiazepine nucleus linked to the pyrimidine
nucleus 11-{4'-[(6"-aryl)-2"-mercapto-3"-4"-dihydro pyrimidine-4"-yl] phenoxy}-
dibenzo [b,f] thiazepines have been synthesised by the condensation of 11-{4'-
[(3"-aryl)-2"-propene-1"-one]-phenoxy} dibenzo [b,f] thiazepines of  Type (IX)
with thiourea  in presence of catalytic amount of alcoholic potassium hydroxide.
The constitution of the products were supported by the elemental analysis,
IR, 1H NMR and Mass spectral studies. The products were tested for their
antimicrobial activity with  MIC.
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Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; 4000-400 cm-1
(KBr disc)














































































































Intrenal standard : TMS; solvent :DMSO-d6 : Instrument : BRUKER spectrometer
(500 MHz)



































































































































































































































































































































































































































Type : (XI) R = Aryl
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EXPERIMENTAL
SYNTHESIS OF 11-{4'-[(6"ARYL)-2"-MERCAPTO-3",4"-DIHYDRO
PYRIMIDINE-4"-YL]-PHENOXY} DIBENZO [b,f] THIAZEPINES
(A) Synthesis of 11-(4'-acetyl phenoxy) dibenzo [b,f] thiazepine
See Part - VI, Section - I, Page No. 139.
(B) Synthesis of 11-{4'-[3"-(4'''-methoxy phenyl)-2"- propene -1"-one]-
phenoxy} dibenzo [b,f] thiazepine
See part - VI, Sextion-I, Page No. 139.
(C) Synthesis of 11-{4'-[6"-(4"'-methoxy phenyl)-2"-mercapto-3",4"-
dihydro pyrimidine-4"-yl]-phenoxy} dibenzo [b,f] thiazepine
A mixture of 11-{4'-[3"-(4"'-methoxy phenyl)-2"-propene-1"- one] phenoxy}
dibenzo [b,f] thiazepine (4.63 gm, 0.01 M) and thiourea (0.76 gm, 0.01 M) was
refluxed at 90oC for 14 hrs in presence of basic medium alcoholic KOH and
methanol. The reaction mixture was poured in to crushed ice, filtered and dried.
The product was isolated and crystalised from methanol. Yield : 74.66 % ; M.P.:
240oC (Found : C:69.09; H: 4.41;N: 8.02; C30H23O2N3S2 calcd. C: 69.01;
H : 4.36; N : 8.06 %)
Similarly other pyrimidines were synthesised and their physical constants
are recorded in Table No. 21.
(D) Biological screening of 11-{4'-[(6"-aryl)-2"-mercapto-3",4"-dihydro
pyrimidine-4"-yl] phenoxy} dibenzo [b,f] thiazepine
The antimicrobial testing was  carried out as describe in Part-I,
Section-I, Page : No. 26-29.
The minimum inhibition concentration is recorded in Table No 22.
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MASS FRAGMENT  STUDY OF 11-{4'-[3"-(4"'-METHOXY PHENYL)-2"-PROPENE-1"-ONE]-PHENOXY}
DIBENZO [b,f] THIAZEPINE
m/z = 210














MASS SPECTRAL  STUDY OF 11-{4'-[5"-(4"'-METHOXY PHENYL)-4"-5"-DIHYDRO-1"-(H)-PYRAZOL-3"-










































MASS FRAGMENT  STUDY OF 11-{4'-[5"-(4"'-METHOXY PHENYL)-4"-5"-DIHYDRO-1"-(H)-PYRAZOL-3"-
YL]-PHENOXY} DIBENZO [b,f] THIAZEPINE














MASS SPECTRAL STUDY OF11-{4'-[6"-(4"'-METHYL PHYNYL)-2"-MERCAPTO-3",4"-DIHYDRO



























































MASS FRAGMENT STUDY OF11-{4'-[6"-(4"'-METHYL PHYNYL)-2"-MERCAPTO-3",4"-DIHYDRO
PYRIMIDINE-4"-YL]-PHENOXY} DIBENZO [b,f] THIAZEPINE
m/z = 414
m/z = 433
m/z = 210
m/z = 505
m/z = 355
m/z = 295
m/z = 114
m/z = 302
m/z = 241
m/z = 279
m/z = 447
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